- Reaction score
- 1,104
Very true! Nice post! And because of the rest DHT, we need to fully block androgens from AR signaling.
Exploring The Hormonal Route. Hair=life.
- Thread starter bridgeburn
- Start date
Patience young grasshopper. You will be growing massive locks soon enough.YeahI am really desperate, dont know what to do. I actually am thinking of doing an orchiectomy and supplementing E to just stop this disease. I am getting mentally ill, and cry about it a lot.
- Reaction score
- 1,104
Well, he will be bald soon, if he won't do smt against it...
- Reaction score
- 1,104
And some nice huge milkers! Can't wait to feed you all ma babieess
- Reaction score
- 529
yeah he will be bald in 30 years for sure
- Reaction score
- 2,035
This is an upgrade which is a common practice in terms of maintaining contact with and providing insight to people especially inter
<blushes>
- Reaction score
- 529
i have my own milkers tyvm
- Reaction score
- 2,035
I was turned down twice for HRT with an endo since I wouldn't sign an SRS contract in 2016 and 2017. Only after Jenner and the non-binary movement did things change.... Now the U.S. leads the world in making these medications available and complete covered along with SRS, BA, thyroid surgery and vocal cord shortening. Things changed literally overnight.
- Reaction score
- 2,035
Moooo! Soon MtF's will be feeding the masses.....
- Reaction score
- 2,035
Our onliest article on Bica for feminization says that it is great for boobs! Hooray! And Particularly This is True for the Very Young, Under 25!
100% of patients experienced breast development while on bicalutamide alone
The potent androgen receptor blocker bicalutamide represents a potential alternative approach to GnRHas in natal males. Other antiandrogens used in transgender females include spironolactone and cyproterone acetate. However, both are far less potent than bicalutamide and their use has primarily been limited to adults [1,3]. In contrast, bicalutamide has been used in the treatment of familial male precocious puberty and other forms of peripheral precocious puberty in young boys [4–6]. One of the most common side effects of bicalutamide is breast development due to an alteration in the ratio of androgens to estrogens. Our experience with the use of bicalutamide in precocious puberty formed the basis for the use of this medication in male-to-female (MTF) patients with GD as a strategy for blocking puberty when GnRHas are denied. Interestingly, the resulting “side effect” of breast development has been welcomed by these patients, all of whom are eager to receive cross-hormone treatment (in this case, estrogen) and to undergo feminizing changes. We are not aware of any previous reports of utilizing bicalutamide as a way to block puberty and promote feminization in the transgender MTF population.
Anecdotally, all patients were extremely positive regarding the breast development they experienced on bicalutamide therapy.
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents - PMC
The purpose of the study was to describe the novel use of bicalutamide in transgender youth. This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Of 104 patients ...
www.ncbi.nlm.nih.gov
100% of patients experienced breast development while on bicalutamide alone
The potent androgen receptor blocker bicalutamide represents a potential alternative approach to GnRHas in natal males. Other antiandrogens used in transgender females include spironolactone and cyproterone acetate. However, both are far less potent than bicalutamide and their use has primarily been limited to adults [1,3]. In contrast, bicalutamide has been used in the treatment of familial male precocious puberty and other forms of peripheral precocious puberty in young boys [4–6]. One of the most common side effects of bicalutamide is breast development due to an alteration in the ratio of androgens to estrogens. Our experience with the use of bicalutamide in precocious puberty formed the basis for the use of this medication in male-to-female (MTF) patients with GD as a strategy for blocking puberty when GnRHas are denied. Interestingly, the resulting “side effect” of breast development has been welcomed by these patients, all of whom are eager to receive cross-hormone treatment (in this case, estrogen) and to undergo feminizing changes. We are not aware of any previous reports of utilizing bicalutamide as a way to block puberty and promote feminization in the transgender MTF population.
Anecdotally, all patients were extremely positive regarding the breast development they experienced on bicalutamide therapy.
Last edited:
- Reaction score
- 2,035
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents - PMC
The purpose of the study was to describe the novel use of bicalutamide in transgender youth. This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Of 104 patients ...
www.ncbi.nlm.nih.gov
We have found that bicalutamide appears to be effective in decreasing androgen exposure with the welcome side effect in these adolescents of promoting feminization. We suspect that the relatively rapid breast enlargement is because of the high potency and purely antagonistic action of bicalutamide on the androgen receptor, leading to increased testosterone levels that are subsequently aromatized to estrogen. In those tested, liver enzymes remained normal, and estradiol levels were above 20 pg/dl with only one exception. There were no apparent adverse effects of bicalutamide in our patients. However, our results must be considered extremely preliminary, and additional data are needed. How bicalutamide might compare to other androgen receptor blockers in terms of safety and efficacy in the adolescent age group is unknown, and the risk for liver toxicity needs to be investigated in larger sample sizes and over a longer duration of time.
The limitations of this study are its small size, minimal laboratory testing, and retrospective nature. Another limitation is that the efficacy of androgen suppression can only be monitored clinically, as testosterone levels actually increase. However, our results suggest that bicalutamide may be an option for transgender MTF adolescents who are denied GnRHas and are also ready for physical feminization. Bicalutamide is also significantly less costly than GnRHas, which costs thousands of dollars per dose. Larger, prospective studies with a more diverse patient population are needed to further evaluate the safety and potential role of bicalutamide in the therapeutic armamentarium for the treatment of transgender MTF youth.
This is good because it suggests that the higher the dosage, the higher the E levels in the tissues, which is beneficial for the hair. Because the information on dosages and blood E levels is rather strangeOur onliest article on Bica for feminization says that it is great for boobs! Hooray! And Particularly This is True for the Very Young, Under 25!
Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents - PMC
The purpose of the study was to describe the novel use of bicalutamide in transgender youth. This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. Of 104 patients ...www.ncbi.nlm.nih.gov
100% of patients experienced breast development while on bicalutamide alone
The potent androgen receptor blocker bicalutamide represents a potential alternative approach to GnRHas in natal males. Other antiandrogens used in transgender females include spironolactone and cyproterone acetate. However, both are far less potent than bicalutamide and their use has primarily been limited to adults [1,3]. In contrast, bicalutamide has been used in the treatment of familial male precocious puberty and other forms of peripheral precocious puberty in young boys [4–6]. One of the most common side effects of bicalutamide is breast development due to an alteration in the ratio of androgens to estrogens. Our experience with the use of bicalutamide in precocious puberty formed the basis for the use of this medication in male-to-female (MTF) patients with GD as a strategy for blocking puberty when GnRHas are denied. Interestingly, the resulting “side effect” of breast development has been welcomed by these patients, all of whom are eager to receive cross-hormone treatment (in this case, estrogen) and to undergo feminizing changes. We are not aware of any previous reports of utilizing bicalutamide as a way to block puberty and promote feminization in the transgender MTF population.
Anecdotally, all patients were extremely positive regarding the breast development they experienced on bicalutamide therapy.
Attachments
- Reaction score
- 2,035
Spikes and half-lives are interesting in terms of our needing more research. Somehow pills seem to feminize when swallowed without especially long half-lives or long periods of spiking compared to injections. It might be that brief spiking works towards feminization. Sucking on pills ups E levels much quicker in the short-run but in terms of long run feminization, I find little to support the notion that any ingestion levels work better than good old fashion pills albeit with a slight increase in liver distress long-term. Sucking also produces different metabolites which still doesn't seem to make a difference except for the psychological effects of estradiol which can be addictive and compelling....Oh wow thank you for your nice words...
Interesting study, what do you think of cycling on and off Cypro 6mg to prevent spiking T? Or how can we deal against spiking T while on Bica!? I mean, we actually need the spiking T, so it can aromatize, but what if the excess T is unhealthy!? As in IGF-1 spikes, as you said...
- Reaction score
- 2,035
At your age without time, hopefully, for significant dormancy and/or fibrosis, it should be plenty.
- Reaction score
- 2,035
I find these curves bizarre with little to explain what is going on as normal dosage curves like say for finasteride and duta level out fairly quickly.
